Detail
| LncRNA Name | MEG3 |
| Synonyms | MEG3, FP504, GTL2, LINC00023, NCRNA00023, PRO0518, PRO2160, onco-lncRNA-83, prebp1 |
| Region | GRCh38_14:100779410-100861031 Sequence |
| Ensembl | ENSG00000214548 |
| RefSeq | NR_002766 |
| Circulating | ✘ |
| Drug-resisitant | ✘ |
| Prognostic | ✔ |
| MiRNA | ✘ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | colorectal cancer |
| ICD-0-3 | C19.9 |
| Methods | qPCR |
| Sample | Human colorectal cancer cell lines (HT29, SW480) |
| Expression Pattern | down-regulated |
| Function Description | In conclusion, our integrated approach demonstrated that decreased expression of lncRNA MEG3 in CRC confers potent poor therapeutic efficacy, and that MEG3 promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis. Thus, overexpression of MEG3 may be a future direction by which to develop a novel therapeutic strategy to overcome oxaliplatin resistance of CRC patients. |
| Pubmed ID | 28731151 |
| Year | 2017 |
| Title | MEG3 is a prognostic factor for CRC and promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis. Overall survival (OS) was updated on February 1, 2012 and was defined as the time from inclusion to death for any reason. Recurrence-free survival (RFS) was defined as the time from inclusion to recurrence or metastatic progression. |
| External Links |
| Links for MEG3 | GenBank HGNC lncrnadb Noncode |
| Links for colorectal cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.